Noninvasive assessment of hepatic fibrosis using gadoxetate-disodium-enhanced 3T MRI
Journal Title: Annals of Hepatology - Year 2013, Vol 12, Issue 6
Abstract
Introduction. Gadoxetate-disodium is a liver-specific MR contrast agent absorbed by hepatocytes via organic anion transporting polypeptide 1B3 and is excreted into the biliary system by multidrug resistance-associated protein 2. It has been suggested that relative parenchymal enhancement on hepatocyte phase image is associated with hepatic function. However, it is not clear whether gadoxetate-disodium-enhanced MRI can be used as a noninvasive fibrosis marker. Thus, the purpose of our study was to evaluate the diagnostic performance of gadoxetate-disodium-enhanced MRI in predicting the hepatic fibrosis stage. Materials and methods. A total of 113 patients who had fibrosis staged according to the Batts and Ludwig score were enrolled: F0 (n = 13), F1 (n = 18), F2 (n = 15), F3 (n = 32), and F4 (n = 35). All patients underwent gadoxetate-disodium-enhanced MRI before confirmation by biopsy (n = 67) or surgery (n = 46). For quantitative analysis, the contrast enhancement index (CEI) was calculated by measuring the signal intensity (SI) in liver and paraspinal muscle using a region of interest, as follows: CEI = (liver SI/paraspinal muscle SI) 20 min hepatocyte phase image/(liver SI/paraspinal muscle SI) pre-contrast T1-weighted image. The diagnostic performance was evaluated by the ROC curve, adjusted for the prevalence of each fibrosis stage. Results. A significant negative correlation was observed between CEI and fibrosis stage (r = -0.545, P < 0.0001). The adjusted AUROC for CEI in the prediction of mild (≥F1), moderate (≥ F2), or severe fibrosis (≥ F3) and liver cirrhosis (F4) was 0.668, 0.703, 0.73, and 0.84, respectively. In conclusion, our results demonstrate that quantitative analysis of relative hepatic enhancement using gadoxetate-disodium-enhanced MRI can predict the hepatic fibrosis stage.
Authors and Affiliations
Yun-Jin Jang, Seung Hyun Cho Cho, Ji Hea Bae, Gab Chul Kim, Hunkyu Ryeom, Hye Jung Kim, Kyung-Min Shin, Hui Joong Lee
Keywords
Related Articles
- EP ID EP78341
- DOI -
- Views 98
- Downloads 0
Nonalcoholic fatty liver disease in asymptomatic obese women
Objective. To determine the clinical characteristics of NAFLD in asymptomatic obese women. Methods. A total of 457 asymptomatic obese women were enrolled in a cross-sectional study and allocated into groups with and with...
Insulin resistance and steatosis in chronic hepatitis C
In chronic hepatitis C, insulin resistance (IR) and type 2 diabetes mellitus (DM) are more prevalent than in healthy controls or in chronic hepatitis B patients. HCV infection promotes IR mainly through increased TNF-a a...
The epidemiologic burden of hepatitis C virus infection in Latin America
Chronic infection with hepatitis C virus (HCV) is a major and growing public health concern worldwide, including in Latin America. With more efficacious therapies becoming available, decision-makers will require accurat...
Caspase recruitment domains. New potential markers for diagnosis of hepatocelular carcinoma associated with HCV in Egyptian patients
Background and rational for the study. Chronic HCV is a major cause of HCC development. Caspase Recruitment Domains (CARD) is protein modules that regulate apoptosis and play an important role in various carcinogenesis p...
Oral Acetyl-L-Carnitine treatment in hepatic encephalopathy: view of evidence-based medicine
Objective. To systematically review the effect of Acetyl-L-Carnitine in patients with hepatic encephalopathy.Material and methods. Design: systematic review and meta-analysis. Data sources: The Cochrane Library, MEDLINE,...